By Professor Sean Emery

Journal articles

Tavel JA; Babiker A; Carey C; Fisher M; Fox L; Gey D; Lopardo GD; Lopez JC; Markowitz N; Munroe D; Paton N; Ruxrungtham K; Standridge B; Wentworth D; Wyman N; Aagaard B; Borup L; Grarup J; Jansson PO; Jensen K; Lundgren J; Mollerup D; Reilev S; Braimah N; Darbyshire J; Horton J; King E; Smith N; Van Hooff F; Cooper DA; Courtney-Rodgers D; Emery S; Finley E; Gordin F; Sánchez A; Thomas D; Bebchuk J; Bollenbeck P; Denning E; DuChene AG; Fosdick L; Harrison M; Krum E; Larson G; Neaton JD; Nelson R; Quan K; Quan SFL; Schultz T; Thompson G; Collins S; Haerry DH; Meulbroek M; Peavy D; Rappoport C; Schwarze S; Valdez M; Watson J; Belloso WH; Davey R; Duprez D; Gatell JM; Hoy J; Lifson A; Pederson C; Perez G; Price R; Prineas R; Rhame F; Sampson JH; Worley J; Modlin JF; Beral V; Chaisson RE; Fleming TR; Hill C; Kim KM; Murray BE; Pick B; Seligmann M; Weller I; Luzar MA; Martinez A; Costas V; Eckstrand J; Brown S; Lupo SH; Losso MH; Anderson J; Chuah J; Kelly M; Orth D; Wolff MJ; Rusconi S; Tambussi G; Horban A; Antunes F; Mansinho K; Da Conceicao Vera JAV; Himmich H, 2010, 'Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: The STALWART study', PLoS ONE, 5, http://dx.doi.org/10.1371/journal.pone.0009334

Sellier P; Lafuente-Lafuente C; Bergmann J-F, 2010, 'Interleukin-2 Therapy in Patients with HIV Infection', NEW ENGLAND JOURNAL OF MEDICINE, 362, pp. 270 - 271, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000273738400020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lifson A; Belloso W; Davey R; Duprez D; Gatell J; Hoy J; Krum E; Nelson R; Pedersen C; Perez G; Price R; Prineas R; Rhame F; Sampson J; Worley J, 2010, 'Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials', HIV Clinical Trials, 11, pp. 205 - 219, http://dx.doi.org/10.1310/hct1104-205

Pett SL; Zaunders J; Bailey M; Murray JM; Macrae K; Emery S; Cooper DA; Kelleher AD, 2010, 'A novel Chemokine-Receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection', AIDS Research and Human Retroviruses, 26, pp. 653 - 661, http://dx.doi.org/10.1089/aid.2009.0278

Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D, 2010, 'A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count', Journal of Infectious Diseases, 202, pp. 1529 - 1537

Martin A; Amin J; Cooper DA; Carr AD; Kelleher AD; Bloch M; Baker D; Woolley I; Emery S, 2010, 'Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial', AIDS, 24, pp. 2657 - 2663

Hemachandra A; Puls R; Sirivichayakul S; Kerr SJ; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher AD; Ruxrungtham K, 2010, 'An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection', Human Vaccines, 6, pp. 835 - 840

Pett SL; Emery S; Kelleher AD; Cooper DA, 2010, 'Antiretroviral agents: Focus on maraviroc for the treatment of HIV-1-infected adults', Clinical Medicine Insights: Therapeutics, 2, pp. 697 - 713, http://www.la-press.com/

Pett SL; Emery S; Kelleher AD; Cooper DA, 2010, 'Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults', Clinical Medicine Insights: Therapeutics, 2, pp. CMT.S5420 - CMT.S5420, http://dx.doi.org/10.4137/cmt.s5420

Wright EJ; Grund B; Robertson K; Brew BJ; Roediger M; Bain MP; Drummond F; Vjecha MJ; Hoy J; Miller C; Penalva de Oliveira AC; Pumpradit W; Shlay JC; El-Sadr W; Price RW, 2010, 'Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons', Neurology, 75, pp. 864 - 873

Lampe FC; Duprez DA; Kuller LH; Tracy R; Otvos J; Stroes E; Cooper DA; Hoy J; Paton NI; Friis-Moller N; Neuhaus J; Liappis AP; Phillips AN, 2010, 'Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 54, pp. 275 - 284

Winston A; Duncombe C; Li P; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA, 2010, 'Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study', Clinical Infectious Diseases, 50, pp. 920 - 929

Puls R; Srasuebkul P; Petoumenos K; Boesecke C; Duncombe CJ; Belloso WH; Molina J; Li L; Avihingsanon A; Gazzard B; Cooper DA; Emery S, 2010, 'Efavirenz versus boosted atazanavir or zidovudine and abacavir in antirectroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study', Clinical Infectious Diseases, Oct 1; 51, pp. 855 - 864

Dore GJ; Soriano V; Rockstroh J; Kupfer B; Tedaldi E; Peters L; Neuhaus J; Puoti M; Klein M; Mocroft A; Clotet B; Lundgren JD, 2010, 'Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption', AIDS, 24, pp. 857 - 865

Achhra A; Amin J; Law MG; Emery S; Gerstoft J; Gordin F; Vjecha M; Neaton JD; Cooper DA, 2010, 'Immunodeficiency and the risk of serious clinical endpoints in a well-studied cohort of treated HIV-infected patients.', AIDS, 24, pp. 1877 - 1886

Carey DL; Amin J; Boyd MA; Petoumenos K; Emery S, 2010, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomised controlled trials', Journal of Antimicrobial Chemotherapy, 65, pp. 1878 - 1888

Neuhaus J; Jacobs DR; Baker JV; Calmy A; Duprez D; La Rosa A; Kuller LH; Pett SL; Ristola M; Ross M; Shlipak MG; Tracy R; Neaton JD, 2010, 'Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection', Journal of Infectious Diseases, 201, pp. 1788 - 1795

Pett SL; Kelleher AD; Emery S, 2010, 'Role of interleukin-2 inpatients with HIV infection', Drugs, 70, pp. 1115 - 1130

Amin J; De lazzari E; Emery S; Martin A; Martinez E; Carr AD; Gatell J; Cooper DA, 2010, 'Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in treatment experienced, virologically suppressed adults with HIV infection: combined analysis of two randomised, non-inferiority trials Bicombo and Steal.', Journal of AIDS & Clinical Research, 1, pp. 1001 - 1013, http://dx.doi.org/10.4172/2155-6113.1000103

Neaton JD; Neuhaus J; Emery S, 2010, 'Soluble biomarkers and morbidity among people infected with HIV: summary of published reports from 1997 to 2010', Current opinion in HIV & AIDS, 5, pp. 480 - 490

Martinez E; Visnegarwala F; Grund B; Thomas A; Gibert C; Shlay J; Drummond F; Pearce D; Edwards S; Reiss P; El-Sadr W; Carr AD, 2010, 'The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters', AIDS, 24, pp. 353 - 363

French MA; Tanaskovic S; Law MG; Lim A; Fernandez S; Ward LD; Kelleher AD; Emery S, 2010, 'Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcγRIIa genotype', AIDS, 24, pp. 1938 - 1990

Grund B; Neuhaus J; Phillips A, 2009, 'Relative risk of death in the SMART study', LANCET INFECTIOUS DISEASES, 9, pp. 724 - 725, http://dx.doi.org/10.1016/S1473-3099(09)70302-0

Hemachandra A; Puls RL; Kerr SJ; Saengthong N; Pussadee K; Emery S; Phanuphak P; Ruxrungtham K, 2009, 'P15-01. Willingness to participate in actual preventive HIV vaccine phase I/IIa trial in Bangkok, Thailand', Retrovirology, 6, http://dx.doi.org/10.1186/1742-4690-6-S3-P202

Wang D; Larder B; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; D'Arminio Monforte A; Torti C; Zazzi M; Lane C, 2009, 'A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy', Artificial Intelligence in Medicine, 47, pp. 63 - 74, http://dx.doi.org/10.1016/j.artmed.2009.05.002

Lazovski J; Losso M; Krohmal B; Emanuel EJ; Grady C; Wendler D, 2009, 'BENEFITS AND BURDENS OF PARTICIPATION IN A LONGITUDINAL CLINICAL TRIAL', JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS, 4, pp. 89 - 97, http://dx.doi.org/10.1525/jer.2009.4.3.89

Phillips A; Emery S, 2009, 'Editorial introductions', Current Opinion in HIV and AIDS, 4, http://dx.doi.org/10.1097/COH.0b013e32832aad28

Mocroft A; Wyatt C; Szczech L; Neuhaus J; El-Sadr W; Tracy R; Kuller L; Shlipak M; Angus B; Klinker H; Ross M, 2009, 'Interruption of antiretroviral therapy is associated with increased plasma cystatin C', AIDS, 23, pp. 71 - 82, http://dx.doi.org/10.1097/QAD.0b013e32831cc129

Pett SL; Mccarthy M; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki J; Williams KM; Emery S, 2009, 'A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients', Antiviral Therapy, 14, pp. 111 - 115

Rodger A; Fox Z; Lundgren JD; Kuller LH; Boesecke C; Gey D; Skoutelis ; Goetz M; Phillips AN, 2009, 'Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection', Journal of Infectious Diseases, 200, pp. 973 - 983, http://dx.doi.org/10.1086/605447

Boyd MA; Emery S; Cooper DA, 2009, 'Antiretroviral roll-out: the problem of second-line therapy', Lancet, 374, pp. 185 - 186

Grulich AE, 2009, 'Cancer: The effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation', Current opinion in HIV & AIDS, 4, pp. 183 - 187

Grund B; Peng G; Gibert C; Hoy JF; Isaksson R; Shlay J; Martinez E; Reiss P; Visnegarwala F; Carr AD, 2009, 'Continuous antiretroviral therapy decreases bone mineral density', AIDS, 23, pp. 1519 - 1529

Samaras K; Wand HC; Law MG; Emery S; Cooper DA; Carr AD, 2009, 'Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism', Current HIV Research, 7, pp. 454 - 461

Read TRH; Carey DL; Mallon PW; Mijch A; Goodall R; Hudson F; Wand HC; Emery S, 2009, 'Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial', AIDS, 23, pp. 2222 - 2223, http://dx.doi.org/10.1097/QAD.0b013e32832e95f8

Byakwaga H; Zhou J; Petoumenos K; Law MG; Boyd MA; Emery S; Cooper DA; Mallon PW, 2009, 'Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy', HIV Medicine, 10, pp. 143 - 151

Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA, 2009, 'Evolution of CD4+T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression', AIDS Research and Human Retroviruses, 25, pp. 569 - 576

Zaunders J; Munier ML; Seddiki N; Pett SL; Ip S; Bailey M; Xu Y; Brown KJ; Dyer W; Kim MS; De Rose R; Kent SJ; Jiang L; Breit SN; Emery S; Cunningham AL; Cooper DA; Kelleher AD, 2009, 'High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)', Journal of Immunology, 183, pp. 2827 - 2836, http://dx.doi.org/10.4049/jimmunol.0803548

Pett SL, 2009, 'Immunotherapies in HIV-1 infection', Current opinion in HIV & AIDS, 4, pp. 188 - 193

Byakwaga H; Boesecke C; Emery S, 2009, 'Inflammation and gut permeability', Journal of Hiv Therapy, 14, pp. 57 - 60, http://www.thefreelibrary.com/Inflammation+and+gut+permeability.-a0213312726

Abrams A; Levy Y; Losso MH; Babiker AG; Collins G; Cooper DA; Darbyshire JH; Emery S; Fox L; Gordin F; Lane HC; Lundgren JD; Mitsuyasu R; Neaton J; Phillips AN; Routy J; Tambussi G; Wentworth D, 2009, 'Interleukin-2 therapy in patients with HIV infection.', New England Journal of Medicine, 361, pp. 1548 - 1559

Duprez D; Kuller LH; Tracy R; Otvos J; Cooper DA; Hoy JF; Neuhaus J; Paton N; Friis-Moller N; Lampe F; Liappis A; Neaton JD, 2009, 'Lipoprotein particle subclasses, cardiovascular disease and HIV infection', Atherosclerosis, 207, pp. 524 - 529, http://dx.doi.org/10.1016/j.atherosclerosis.2009.05.001

Martin A; Emery S, 2009, 'Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral therapy', Expert Review of Clinical Pharmacology, 2, pp. 381 - 390

Carey DL; Baker D; Petoumenos K; Chuah J; Rogers G; Watson J; Cooper DA; Emery S; Carr AD, 2009, 'Poly-L-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up', HIV Medicine, 10, pp. 163 - 172

Phillips A; Emery S, 2009, 'Predicting the potential benefits of early initiation of ART: Time to do a trial to find out', Current opinion in HIV & AIDS, 4, pp. 165 - 166

Emery S; Winston A, 2009, 'Raltegravir: a new choice in HIV and new chances for research', Lancet, 374, pp. 764 - 766

Martin A; Bloch MT; Amin J; Baker DL; Cooper DA; Emery S; Carr AD, 2009, 'Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial', Clinical Infectious Diseases, 49, pp. 1591 - 1601

Pett SL; Zaunders J; Bailey M; Cooper DA; MacRae K; Emery S; Kelleher A, 2008, 'Changes in CCR5+ cells and antigen-specific CD4+ T-cells during monotherapy with a CCR5 antagonist SCH532706 compared with combination therapy', Journal of the International AIDS Society, 11, http://dx.doi.org/10.1186/1758-2652-11-s1-p297

Byakwaga H; Murray JM; Petoumenos K; Boyd MA; Emery S; Mallon PW; Cooper DA, 2008, 'Evolution of CD4+ T-cell count in HIV-1 infected adults receiving antiretroviral therapy with sustained long-term virological suppression', Journal of the International AIDS Society, 11, http://dx.doi.org/10.1186/1758-2652-11-s1-p70

Burman W; Grund B; Neuhaus J; Douglas J; Friedland G; Telzak E; Colebunders R; Paton N; Fisher M; Rietmeijer C, 2008, 'Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: Results of a randomized controlled trial', JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 49, pp. 142 - 150, http://dx.doi.org/10.1097/QAI.0b013e318183a9ad

Back to profile page